ELI LILLY & CO (1LLY.MI) Stock Price, Forecast & Analysis
Europe • Euronext Milan • BIT:1LLY • US5324571083
1LLY.MI Key Statistics, Chart & Performance
The current stock price of 1LLY.MI is 887.7 EUR. In the past month the price decreased by -3.61%. In the past year, price increased by 15.2%.
1LLY.MI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to 1LLY.MI. When comparing the yearly performance of all stocks, 1LLY.MI turns out to be only a medium performer in the overall market: it outperformed 68.29% of all stocks.
1LLY.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1LLY.MI. While 1LLY.MI has a great profitability rating, there are some minor concerns on its financial health.
1LLY.MI Financial Highlights
Over the last trailing twelve months 1LLY.MI reported a non-GAAP Earnings per Share(EPS) of 20.53. The EPS increased by 86.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.99% | ||
| ROA | 16.02% | ||
| ROE | 77.38% | ||
| Debt/Equity | 1.72 |
1LLY.MI Forecast & Estimates
37 analysts have analysed 1LLY.MI and the average price target is 992.48 EUR. This implies a price increase of 11.8% is expected in the next year compared to the current price of 887.7.
For the next year, analysts expect an EPS growth of 38.64% and a revenue growth 21.61% for 1LLY.MI
1LLY.MI Ownership
1LLY.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.69 | 197.812B | ||
| SAN | SANOFI | 9.51 | 194.092B | ||
| SNW | SANOFI | 9.5 | 193.899B | ||
| 1MRK | MERCK KGAA | 14.2 | 55.739B | ||
| MRK | MERCK KGAA | 14.13 | 52.804B | ||
| UNC | UCB SA | 25.52 | 51.039B | ||
| UCB | UCB SA | 25.48 | 50.962B | ||
| BAYN | BAYER AG-REG | 9.37 | 44.995B | ||
| 1BAYN | BAYER AG-REG | 9.17 | 44.008B | ||
| IPN | IPSEN | 11.93 | 11.406B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1LLY.MI
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA US
Employees: 47000
Phone: 13172762000
ELI LILLY & CO / 1LLY.MI FAQ
What does 1LLY do?
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
What is the stock price of ELI LILLY & CO today?
The current stock price of 1LLY.MI is 887.7 EUR. The price increased by 1.07% in the last trading session.
What is the dividend status of ELI LILLY & CO?
ELI LILLY & CO (1LLY.MI) has a dividend yield of 0.68%. The yearly dividend amount is currently 4.18.
What is the ChartMill technical and fundamental rating of 1LLY stock?
1LLY.MI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Would investing in ELI LILLY & CO be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1LLY.MI.
Can you provide the ownership details for 1LLY stock?
You can find the ownership structure of ELI LILLY & CO (1LLY.MI) on the Ownership tab.